HS
STRO icon

HighVista Strategies’s Sutro Biopharma STRO Stock Holding History

HighVista Strategies’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,898
Closed -$887K – 141
2021
Q1 		$887K Sell
3,898
-2,407
-38% -$571K 0.66% 22
2020
Q4 		$1.37M Sell
6,305
-164
-3% -$27.2K 0.87% 20
2020
Q3 		$651K Buy
+6,469
New +$611K 0.47% 25

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

HighVista Strategies's STRO Position: Q2 2021 in Review

HighVista Strategies sold out of Sutro Biopharma (STRO) in Q2 2021, closing a stake of 3,898 shares — an estimated $887K sold.

HighVista Strategies first reported a position in STRO in Q3 2020 and held it in 3 quarters. The position peaked at $1.37M in Q4 2020. 124 funds tracked by Wall St. Rank hold STRO as of Q2 2021.

  • HighVista Strategies reported no remaining Sutro Biopharma position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 3,898 Sutro Biopharma shares in Q2 2021, an estimated $887K.
  • HighVista Strategies first reported a position in Sutro Biopharma in Q3 2020 and held it in 3 quarters.
  • HighVista Strategies's Sutro Biopharma position peaked at $1.37M in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.